Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Leuk Res. 2017 Nov 11;64:30–33. doi: 10.1016/j.leukres.2017.11.004

Figure 1. Expression of CDK1-AF and CDK2-AF sensitizes T-ALL cells to cytarabine.

Figure 1

A. Jurkat cells transduced with empty vector (pLVX), CDK1-AF, or CDK2-AF constructs were give no treatment (NT) or doxycycline (1 ug/mL) for 48 hr after which protein lysates were subjected to western blotting with antibodies specific to HA-tag and GAPDH. B. Jurkat cells transduced with empty vector (pLVX), CDK1-AF, and/or CDK2-AF were treated with Ara-C (10 nM) and/or doxycycline (1 ug/mL) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean ± SEM from three independent experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001. C. Jurkat cells transduced with empty vector (pLVX), CDK1-AF, and/or CDK2-AF were treated with doxycycline (1 ug/mL) and Ara-C (0.5-40 nM) for 72 hr. Viable cell counts are normalized to cells receiving no Ara-C treatment (NT). Results are shown as mean ± SEM from three independent experiments. IC50 values for each cell line with and without doxycycline are displayed below the corresponding graph.